Previously, we clarified the species differences in P-glycoprotein (P-gp)mediated drug transport activity using human MDR1, monkey MDR1, canine MDR1, rat MDR1a, rat MDR1b, mouse mdr1a, and mouse mdr1b transfected LLC-PK 1 cell lines. However, the species differences in the inhibitory effects on P-gp
Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug–drug interactions
✍ Scribed by Min-Koo Choi; Qing-Ri Jin; Yeong-Lim Choi; Sung-Hoon Ahn; Myung-Ae Bae; Im-Sook Song
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 232 KB
- Volume
- 32
- Category
- Article
- ISSN
- 0142-2782
- DOI
- 10.1002/bdd.749
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Concomitant administration of botanical supplements with drugs that are P‐glycoprotein (P‐gp) substrates may produce clinically significant herb‐drug interactions. This study evaluated the effects of St. John's wort and __Echinacea__ on the pharmacokinetics of digoxin, a recognized P‐gp
## Abstract Increasing experimental, clinical, and epidemiological studies point to the pivotal role of inflammation in the pathogenesis of acute and chronic neurodegenerative diseases and to the protective effects of nonsteroidal antiinflammatory drug (NSAID) therapies. Nonetheless, NSAID long‐ter
Studies on Disease-Modifying Antirheumatic Drugs. Part 3. Bone Resorption Inhibitory Effects of Ethyl 4-(3,4-Dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) and Related Compounds. -Structure-activity relationships concerning the bone resorption inhibitor